Georges Gemayel

Gemayel joined Prosensa Board of Directors in January 2014.

From April 2007 until December 2011, Gemayel served as a director of Adolor Corporation, a public clinical development company that was acquired by Cubist Pharmaceuticals, Inc.

From April 2010 to October 2010, Gemayel served as Executive Chairman of FoldRx Pharmaceuticals, Inc., a privately-held drug discovery and clinical development company that was acquired by Pfizer Inc.

From June 2008 until November 2009, Gemayel served as President, Chief Executive Officer and a director of Altus Pharmaceuticals Inc., a publicly-traded pharmaceutical company.

From 2003 to May 2008, Gemayel served as Executive Vice President Therapeutics and Biosurgery for Genzyme Corporation, where he was responsible for Genzyme's global therapeutics, transplant, renal and biosurgery businesses.

From 2000 to 2003, Dr. Gemayel was employed as Vice President National Specialty Care for Hoffmann-La Roche, responsible for its U.S. business for dermatology, oncology, transplantation, hepatitis and HIV.

Gemayel joined Hoffmann-La Roche in 1988 and served in various positions of increasing responsibility over his tenure there.

Gemayel received his doctorate in pharmacy from St. Joseph University in Beirut, Lebanon and his Ph.D. in Pharmacology from Paris-Sud University.

In November 2009, while Gemayel was President, Chief Executive Officer and a director, Altus Pharmaceuticals filed a voluntary petition for relief under Chapter 7 of the U.S. Bankruptcy Code and ceased operations at such time.

From February 2011 to December 2012, Gemayel served as Executive Chairman of Syndexa Pharmaceuticals Corp., a privately held company.

Gemayel also serves as the Chairman of the Board of Directors of Vascular Magnetics, Inc., Epitherapeutics, and Oxthera and is a member of the Board of Directors of Orphazyme ApS all privately held bio-pharmaceutical companies.

He also serves on the Board of Directors of NPS Pharmaceuticals a publicly traded pharmaceutical company since February 2012.

He is also a Director of the International Institute of New England a non-profit organization.

Georges Gemayel is the Director at Orphazyme, based in Europe. With a background in Biotechnology, Georges Gemayel has a rich history of leadership and innovation.Georges Gemayel studied Ph.D. Pharmacy at Saint Joseph’s University. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.